Cargando…

Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial

BACKGROUND: Obese patients have lower NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels. The prognostic implications of achieving NT‐proBNP levels ≤1000 pg/mL in obese patients with heart failure (HF) receiving biomarker‐guided therapy are not completely known. We evaluated the prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Parcha, Vibhu, Patel, Nirav, Kalra, Rajat, Suri, Sarabjeet S., Arora, Garima, Wang, Thomas J., Arora, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174357/
https://www.ncbi.nlm.nih.gov/pubmed/33754794
http://dx.doi.org/10.1161/JAHA.120.018689
_version_ 1783702893355859968
author Parcha, Vibhu
Patel, Nirav
Kalra, Rajat
Suri, Sarabjeet S.
Arora, Garima
Wang, Thomas J.
Arora, Pankaj
author_facet Parcha, Vibhu
Patel, Nirav
Kalra, Rajat
Suri, Sarabjeet S.
Arora, Garima
Wang, Thomas J.
Arora, Pankaj
author_sort Parcha, Vibhu
collection PubMed
description BACKGROUND: Obese patients have lower NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels. The prognostic implications of achieving NT‐proBNP levels ≤1000 pg/mL in obese patients with heart failure (HF) receiving biomarker‐guided therapy are not completely known. We evaluated the prognostic implications of obesity and having NT‐proBNP levels (≤1000 pg/mL) in the GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker‐Intensified Treatment in HF) trial participants. METHODS AND RESULTS: The risk of adverse cardiovascular events (HF hospitalization or cardiovascular mortality) was assessed using multivariable‐adjusted Cox proportional hazard models based on having NT‐proBNP ≤1000 pg/mL (taken as a time‐varying covariate), stratified by obesity status. The study outcome was also assessed on the basis of the body mass index at baseline. The predictive ability of NT‐proBNP for adverse cardiovascular events was assessed using the likelihood ratio test. Compared with nonobese patients, obese patients were mostly younger, Black race, and more likely to be women. NT‐proBNP levels were 59.0% (95% CI, 39.5%–83.5%) lower among obese individuals. The risk of adverse cardiovascular events was lower in obese (hazard ratio [HR], 0.48; 95% CI, 0.29–0.59) and nonobese (HR, 0.32; 95% CI, 0.19–0.57) patients with HF who had NT‐proBNP levels ≤1000 pg/mL, compared with those who did not. There was no interaction between obesity and having NT‐proBNP ≤1000 pg/mL on the study outcome (P>0.10). Obese patients had a greater risk of developing adverse cardiovascular events (HR, 1.39; 95% CI, 1.01–1.90) compared with nonobese patients. NT‐proBNP was the strongest predictor of adverse cardiovascular event risk in both obese and nonobese patients. CONCLUSIONS: On‐treatment NT‐proBNP level ≤1000 pg/mL has favorable prognostic implications, irrespective of obesity status. NT‐proBNP levels were the strongest predictor of cardiovascular events in both obese and nonobese individuals in this trial. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01685840.
format Online
Article
Text
id pubmed-8174357
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81743572021-06-11 Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial Parcha, Vibhu Patel, Nirav Kalra, Rajat Suri, Sarabjeet S. Arora, Garima Wang, Thomas J. Arora, Pankaj J Am Heart Assoc Original Research BACKGROUND: Obese patients have lower NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels. The prognostic implications of achieving NT‐proBNP levels ≤1000 pg/mL in obese patients with heart failure (HF) receiving biomarker‐guided therapy are not completely known. We evaluated the prognostic implications of obesity and having NT‐proBNP levels (≤1000 pg/mL) in the GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker‐Intensified Treatment in HF) trial participants. METHODS AND RESULTS: The risk of adverse cardiovascular events (HF hospitalization or cardiovascular mortality) was assessed using multivariable‐adjusted Cox proportional hazard models based on having NT‐proBNP ≤1000 pg/mL (taken as a time‐varying covariate), stratified by obesity status. The study outcome was also assessed on the basis of the body mass index at baseline. The predictive ability of NT‐proBNP for adverse cardiovascular events was assessed using the likelihood ratio test. Compared with nonobese patients, obese patients were mostly younger, Black race, and more likely to be women. NT‐proBNP levels were 59.0% (95% CI, 39.5%–83.5%) lower among obese individuals. The risk of adverse cardiovascular events was lower in obese (hazard ratio [HR], 0.48; 95% CI, 0.29–0.59) and nonobese (HR, 0.32; 95% CI, 0.19–0.57) patients with HF who had NT‐proBNP levels ≤1000 pg/mL, compared with those who did not. There was no interaction between obesity and having NT‐proBNP ≤1000 pg/mL on the study outcome (P>0.10). Obese patients had a greater risk of developing adverse cardiovascular events (HR, 1.39; 95% CI, 1.01–1.90) compared with nonobese patients. NT‐proBNP was the strongest predictor of adverse cardiovascular event risk in both obese and nonobese patients. CONCLUSIONS: On‐treatment NT‐proBNP level ≤1000 pg/mL has favorable prognostic implications, irrespective of obesity status. NT‐proBNP levels were the strongest predictor of cardiovascular events in both obese and nonobese individuals in this trial. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01685840. John Wiley and Sons Inc. 2021-03-23 /pmc/articles/PMC8174357/ /pubmed/33754794 http://dx.doi.org/10.1161/JAHA.120.018689 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Parcha, Vibhu
Patel, Nirav
Kalra, Rajat
Suri, Sarabjeet S.
Arora, Garima
Wang, Thomas J.
Arora, Pankaj
Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial
title Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial
title_full Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial
title_fullStr Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial
title_full_unstemmed Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial
title_short Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial
title_sort obesity and serial nt‐probnp levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the guide‐it trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174357/
https://www.ncbi.nlm.nih.gov/pubmed/33754794
http://dx.doi.org/10.1161/JAHA.120.018689
work_keys_str_mv AT parchavibhu obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial
AT patelnirav obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial
AT kalrarajat obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial
AT surisarabjeets obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial
AT aroragarima obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial
AT wangthomasj obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial
AT arorapankaj obesityandserialntprobnplevelsinguidedmedicaltherapyforheartfailurewithreducedejectionfractioninsightsfromtheguideittrial